In November, our research study about symptoms and quality of life for PF patients was published here. This peer-reviewed publication was a pilot study. Our research for people with PF remains promising, with one study ongoing and all the others available at our research page.
What was the latest study, and why was it needed?
The study was called, “Effects of Systemic Enzyme Supplements on Symptoms and Quality of Life in Patients with Pulmonary Fibrosis—A Pilot Study.” It was needed because the treatment options for IPF are very limited.
Despite slowing down disease progression, the current FDA-approved antifibrotic treatments for Idiopathic Pulmonary Fibrosis have little impact on symptoms or quality of life in patients. Because of this, we conducted a study to evaluate the effects of systemic enzymes in relieving symptoms associated with PF and improving quality of life.
What did the study show?
Thirteen people with PF participated in the study. To start, they completed questionnaires about their quality of life. Then they received the oral systemic enzyme supplements Serracor-NK and Serra Rx for 12 weeks, and completed the same questionnaires during that time. At the end, researchers reviewed the data from participants’ quality of life before & after their treatment regimen.
Results showed significant improvement in 61.5% of participants based off the WHO well-being index. The data also showed an improvement in 84.6% of the subjects based off the UCSD Shortness of Breath Questionnaire. Altogether, the results led researchers to the conclusion that systemic enzymes can improve symptoms, mental and physical wellbeing, and health-related quality of life for patients with PF.
Where can I learn more about PF-related research?